Gene editing technology – the CRISPR tech fund

eToro is launching a CRISPR-Tech fund with a minimum investment requirement of US$5,000. Some of these gene editing firms are starting important trials, hoping to receive approval in medicine, agriculture and even human gene editing.

 

eToro users who wish to profit from this hot investment trend but don’t want to risk $5,000 of their hard earned cash could copy a trader investing in the fund.

 

As the genome editing technology is at a trial stage, I have taken the decision to place CFD orders on some of the companies developing CRISPR technology: eg Cellectis SA $CLLS (ZVA / FR0010425595, France), Intellia Therapeutics Inc.  $NTLA (38I / US45826J1051, USA) and TEVA Pharmaceutical Industries Ltd (TEV / US8816242098, Israel).

Other CRISPR-Tech developers I have an eye on are Uniqure B.V.  $QURE (UQ1 / NL0010696654, Netherlands) and CRISPR Therapeutics AG  $1CG (CH0334081137, Switzerland).

 

I have opened CFD positions in some health sector firms in gene editing and pharmaceuticals, taking advantage of yesterday’s dip in CRISPR Technology developers : Sangamo Bioscience Inc ($SGMO), Intellia Therapeutics Inc ($NTLA at $20.90) and Editas Medicine Inc ($EDIT at $30.88), Merk Inc ($MRK at $56.60) and Agilent Technologies Inc ($A at $70.62). Had opened two positions in Cellectis SA ($CLLS at $31.46) of France previously. I have also acquired shares Cellectis SA and in pharmaceutical generics maker TEVA Pharmaceutical Industries Ltd of Israel at €16.12 – $TEV also have a hand in gene editing technology CRISPR.

 

=== update 12/JAN/2018 ===

The CFD orders I placed on CRISPR-Tech developers during this week’s dip have worked well. Only Cellectis SA CLLS  is still in red (opened at $31.46), while Agilent Technologies Inc (A opened at $70.62 +2.73%), Sangamo Biosciences Inc (SGMO opened at $16.87 +7.27%), Intellia Therapeutics Inc (NTLA opened at £20.9 +5.33%) and Editas Medicine Inc (EDIT opened at 30.88 +12.79%) have turned green.

I am also bullish for my share holdings in CRISPR Therapeutics AG  $1CG (CH0334081137, Switzerland) and Cellectis SA (ZVA / FR0010425595, France). The shares in TEVA Pharmaceutical Industries Ltd (TEV / US8816242098, Israel), which I acquired at €16.12 ended the week 2.38% up.

=== update 31/JAN/2018 ===

Acquired shares in CRISPR Therapeutics AG A2AT0Z CH0334081137 of Switzerland at €21.20 on 12/JAN/2018, during the health sector dip on 30 January, I sold CRISPR Therapeutics AG $1CG at €35 and bought back into it the same day at €34.

 

Used the health sector dip on 30 January to finally buy shares in Dutch #CRISPR developper #Uniqure B.V. at €15.50. Unfortunately, $QURE UQ1A1XDTV NL0010696654 sees little volume.

 

=== addition 16/MAR/2018

CALYXT INC of New Brighton, Minnesota uses CRIPSR -Tech to develop crops with improved nutritional and agricultural characteristics. It uses gene editing techniques such as TALEN to change the genome. The former Cellectis SA subsidiary filed for an IPO in June 2017. CALYXT INC ($CLXT WKN: A2DU9F, ISIN: US13173L1070) stock price has dropped since it’s IPO and I feel it at a good level to acquire shares.

5 thoughts on “Gene editing technology – the CRISPR tech fund”

  1. Howdy! Would you mind if I sһare yoսr blog wіth my facebook group?

    There’s a lot of peopⅼe that I think wouⅼd really appreciate your content.
    Please let me know. Thank you

Comments are closed.